Navigation Links
Scios Inc. targets drug giants in arthritis war

Scios Inc. , a small California biotechnology company, is racing giant rivals to bring a pill to market that would displace injectable anti-inflammatory drugs and set a new standard in arthritis treatment. Scios' ambitions are much larger than its market capitalization of a little more than $1 billion. That's because the first company to commercialize an oral version of today's dominant injectable drugs could gain the lion's share of a market. //

Scios' drug has shown promise in early trials. But the size of the potential market makes it a prize that many big pharmaceuticals companies also covet. So far, Scios' prospects look good. The company's pill appears to inhibit an enzyme, known as the p38 kinase, which provokes inflammation.

Scios' lead comes in part because an earlier trailblazer, Vertex Pharmaceuticals Inc. , was forced to drop back after its lead p38 kinase inhibitor showed toxicity in high doses in some animals. There are also many competitors. They include drug giant GlaxoSmithKline, which first isolated the p38 kinase in the early 1990s. Glaxo's drug is in early stage clinical trials for rheumatoid arthritis, asthma and irritable bowel syndrome. Other rivals include Merck and Co. Inc. , Roche Holding Ltd. , Johnson and Johnson, and Amgen Inc.

Scion Inc. has completed trials in healthy humans and is now planning to test the drug in patients with rheumatoid arthritis. Most rivals have yet to reach this stage.
'"/>




Page: 1

Related medicine news :

1. South Africa Wins landmark case against pharmaceutical giants
2. Vedic vibration technology- the new cure for arthritis
3. Tai chi helps arthritis
4. Periodontitis a common problem in patients with arthritis
5. New device for discerning Osteoarthritis
6. Herbal extract aids in rheumatoid arthritis
7. Osteoarthritis and Estrogen are connected
8. Hyaluronan supplementation therapy for Knee Osteoarthritis
9. Green tea beneficial in preventing osteoarthritis
10. Leech Therapy for Osteoarthritis
11. Hydrotherapy Found to be Effective for Patients with Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/24/2017)... ... April 24, 2017 , ... Rod Burkett, CEO of ... News website. , Rod has been at the forefront of Gardant since it was ... CEO, Rod has overseen the opening of more than 40 new senior living communities. ...
(Date:4/24/2017)... ... April 24, 2017 , ... Come to PAINWeekEnd (PWE) Tampa on May ... for an educational and exciting 2-day program. , An attendee at a recent ... they approach patients” about the course entitled Ain't Misbehavin': Decreasing and Managing Pain Patient ...
(Date:4/24/2017)... New York, NY (PRWEB) , ... April 24, ... ... students in 72 countries clearly shows that over the last decade, student well-being ... have ticked all the boxes of formal education, join the Islamic State to ...
(Date:4/24/2017)... ... 24, 2017 , ... “The Saint with Trin, and Omega Station”: a triple ... the creation of published author, Chris Jackson. Chris Jackson grew up in Abilene, ... Dallas Independent School District teaching English. He is heavily involved in the youth group ...
(Date:4/24/2017)... NC and Seattle, WA (PRWEB) , ... April ... ... utilized by 75+ leading lifestyle brands, work wear distributors and International relief organizations ... they can carry. The company also offers lifestyle and work wear collections via ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 The Mobile X-Ray product segment ... healthy CAGR during the forecast period Mobile X-Ray ... global digital mobile X-Ray devices market, which is estimated to ... expanding at a CAGR of 7% over the forecast period. ... of more than US$ 100 Mn in 2017 over 2016. ...
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
Breaking Medicine Technology: